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Reproductive Health in Women Following Abdominal Solid Organ Transplant 
 
Monika Sarkar, Kate Bramham, Michael Moritz, and Lisa Coscia   
 
 
 
Abstract: Fertility is typically impaired in women with end-stage kidney and liver disease 
although most women will have restoration of fertility within a year of transplant. Family 
planning is therefore critical to discuss with reproductive aged transplant recipients in the 
early post transplant period, in order to ensure timely initiation of contraception, and 
optimal timing for conception. For women seeking pregnancy the risks to the mother, 
graft, and baby should be discussed including evaluation of immunosuppression safety 
and potential for adjusting medications prior to conception. With an increasing number of 
transplant patients now breastfeeding, immunosuppression safety in lactation continues 
to carry great importance. 
 
Fertility in the pre- and post-transplant setting 
End stage renal disease (ESRD) and end stage liver disease (ESLD) are associated 
with impaired fertility in women. Nearly three quarters of women listed for liver transplant 
have secondary amenorrhea, with cessation of menstrual cycles in the setting of 
progressive liver disease.(1) Similar patterns have long been noted in women with 
ESRD with more than 90% of women on dialysis having irregular or absent menstrual 
cycles.(2) Although the exact etiology leading to impaired fertility is not known, both 
disease states are characterized by dysregulation in the hypothalamic-pituitary-ovarian 
(HPO) axis with abnormal increase in prolactin secretion from the pituitary gland. 
Prolactin inhibits gonadotropin-releasing hormone (GnRH), impairing the pulsatile 
release of FSH and LH, which is critical for ovulation. The HPO dysregulation is further 
exacerbated in ESRD by impaired renal clearance of prolactin. After liver and kidney 
transplant, hormonal levels normalize (1, 3), and the majority of women will resume 
regular menstrual cycles within one-year post transplant, though menses may resume as 
early as one-month post transplant. The earliest pregnancy has occurred within one first 
month after liver transplant (LT), highlighting the importance of reproductive counseling 
and family planning in the initial post transplant period.   
 
Contraception in Transplant Recipients: 
As the majority of women awaiting transplant are amenorrheic, pregnancy concerns and 
restored fertility may not come to mind. In a U.S. study of reproductive-aged kidney 
transplant (KT) and LT recipients, only half of women used any form of contraception, 
and 44% were not aware that pregnancy was possible after transplant.(4) In another 
study of KT/LT recipients nearly half were using no contraception, and ~ 40% of women 
were relying upon high failure methods such as condoms, rhythm, or withdrawal.(5) 
Among women who conceived posttransplant, more than a third had unplanned 
pregnancies. It is therefore important that transplant providers discuss family planning in 
the early transplant period to ensure timely initiation of effective methods. 
 
Intrauterine devices (IUDs) 
Intrauterine devices (IUDs), including copper (ie Paraguard®) or hormonal (ie Skyla® or 
Mirena®), are among the most effective contraceptive methods available. According to 
the Centers for Disease Control (CDC), failure rates in the general population are < 1% 
(0.8% for copper IUDs and 0.2% for hormonal), which contrasts with high failure rates of 
non-hormonal methods such as condoms (18%), rhythm (24%), or withdrawal (22%). 
Copper IUDs may be used for up to 12 years, and result in localized inflammation that 
creates a hostile environment for the survival of sperm. As copper IUDs are non 
hormonal, women maintain regular menstrual cycles. Menstrual bleeding with the copper 
IUD is often heavier, which is less ideal for women with existing posttransplant anemia. 
Hormonal IUDs are effective for 3-5 years, depending on the specific brand, and often 
result in lighter and less frequent menses. 
 
Concerns surrounding the use of IUDs stemmed from a 1980s case report of two 
adolescent KT recipients who became pregnant while using the copper IUD.(6) It was 
postulated that immunosuppression (IMS) may lower the inflammatory response needed 
for IUD efficacy. However, the local inflammatory response of IUDs is a macrophage 
driven process, therefore not affected by transplant IMS.(7) The largest study in the 
transplant population included 647 KT recipients, 178 of whom were using IUDs. While 
15% of the cohort had an unwanted pregnancy, no pregnancies occurred in the IUD 
group.(8) Similar results were reported in KT and LT recipients using hormonal IUDs, 
with no pregnancies in 3 years of follow-up.(9-11) Current IUDs are also well studied in 
immunosuppressed women, and have no greater risk of pelvic inflammatory disease 
(PID) than in the general population of non-IUD users.(12, 13) There have been no 
cases of PID among > 200 KT and LT recipients with published IUD use to date.(6, 8, 9, 
11)   
 
Combined hormonal contraception (CHC) 
CHC contains estrogen and progestin, and works primarily by impairing ovulation. 
Delivery methods include oral contraceptive pills (OCPs), the transdermal patch, and 
vaginal ring. Failure rates are ~ 9%, therefore higher than that of IUDs. Safety concerns 
in the general population include risk of venous thromboembolism, stroke, and elevated 
blood pressure. These agents are metabolized by cytochrome P450 therefore 
medications that induce P450, may reduce their efficacy. Older formulations were 
commonly associated with liver enzyme elevation, though current agents carry only rare 
risk of cholestatic liver injury.(14) There are no controlled studies evaluating side effects 
in transplant patients.(15) In an uncontrolled study of 36 KT recipients using OCPs or the 
patch approximately one third required increased blood pressure medication, 1 
developed thrombophlebitis, and another had graft failure 10 years post transplant.(16) 
In a 1-year follow-up of 16 LT recipients no embolic events or elevated blood pressure 
was noted.(17)  
 
Progestin-only agents 
Progestin only contraception does not carry increased risk of hypertension or VTE, 
though the failure rate is still ~9%. Depo-provera is an intramusclular injection given 
every 12 weeks, with a failure rate of ~6%. Unfortunately a black box warning was 
issued by the Food and Drug Administration (FDA) in 2004 given associated decline in 
bone mineral density. Although bone density normalizes with discontinuation (18) there 
are lingering concerns for transplant patients given baseline osteomalacia in the setting 
of renal disease, and the additional risk of osteopenia related to post transplant steroid 
use. The subcutaneous implant (ie Nexplanon®) is not associated with bone loss, 
though no studies have evaluated its use in transplant patients. In the general population 
the implant carries the lowest failure rate of all hormonal agents (0.05%).  
 
In 2013, the CDC published the U.S. Selected Practice Recommendations for 
Contraceptive Use (U.S. SPR) and includes formal recommendations for contraceptive use 
in solid organ transplant, which are graded as: 1 = No restriction, 2 = Benefits outweigh 
theoretical or proven risks, 3 = Risks outweigh benefits, and 4 = Unacceptable risk 
(Figure 1). These recommendations are separately provided for stable or complicated 
graft function (the latter defined as acute or chronic graft failure, rejection, or cardiac 
allograft vasculopathy). All hormonal methods are considered safe in women with stable 
grafts. Only progestin-only agents have a favorable safety grade “2” although these 
recommendations have not incorporated additional larger studies also demonstrating 
favorable IUD safety data.(11, 19) The CDC does note that with graft dysfunction 
existing IUDs may be left in place. CHC carries an unacceptable risk for complicated 
graft function, and should be discontinued. We consider IUDs first line for KT and LT 
patients with both complicated and uncomplicated graft function given their favorable 
safety and efficacy data. 
 
Pregnancy outcomes in transplant recipients  
For reproductive aged women seeking pregnancy after transplant, timing is key. In 2005 
the American Society of Transplantation issued a consensus statement advising deferral 
of pregnancy for at least one year after solid organ transplant.(20) Delaying pregnancy 
helps to ensure stable graft function with the lowest levels of immunosuppression, and 
therefore also lowest risk of infectious complications.(21) When considering pregnancy, 
recipients and providers should be aware of potential  risks, including risks to the graft, 
as well as risks to the baby. Pregnancy in the setting of solid organ transplant is higher 
risk, although with coordinated care among the various specialists, the majority of KT 
and LT recipients (~ 75%) will have successful deliveries.(22, 23)  
 
A higher proportion of transplanted women are delivered by caesarean section than non-
transplant recipients.(22, 23) The type of delivery should be guided by obstetric 
indications, rather than history of transplant. Vaginal delivery is not contraindicated in 
women with LT or KT, nor do their previous surgical procedures affect uterine 
expansion. There is potential for inadvertent renal allograft damage during caesarean 
section therefore knowledge of its anatomical location is required by obstetricians prior 
to surgical delivery. 
 
Maternal/graft risks 
Hypertension during pregnancy is more common in transplant patients than in non-
transplant controls (24), due in part to the hypertensive side effects of 
immunosuppressive agents. As the majority of transplant recipients require lifelong 
immunosuppression, the Transplant Pregnancy Registry (TPR) International (formerly 
the National Transplantation Pregnancy Registry), was established in 1991 to study 
pregnancy outcomes in all sold-organ transplant recipients. Listed in Table 1 are the 
pregnancy outcomes reported to the TPR in KT and LT recipients. Hypertension in 
pregnancy is twice as common in KT as compared to LT recipients (22, 23) (Table 1), 
which likely relates to longstanding hypertension prior to transplant leading to chronic 
endothelial damage. Diabetes is also more common in KT recipients prior to transplant, 
and given greater immunosuppression (IMS) needs in KT recipients, their risks of HTN 
and DM may be exacerbated by IMS-related side effects. Prevalence of gestational 
diabetes is also higher in KT recipients at ~ 8%, compared to 5% in LT recipients, and < 
4% of non transplant controls.(25) This would be detected during routine pregnancy 
care. 
 
Whether pregnancy increases risk of rejection or graft loss remains controversial. The 
prevalence of rejection during pregnancy in the TPR is reported at 0.9% for KT and 3.4% 
for LT patients, with a prevalence of 1.4% and 4.2% respectively in the first 3 months 
post partum (Table 1). Graft loss within 2 years of transplant is 5.9% in KT and 3.5% in 
LT patients, neither of which are greater than in non-pregnant controls. Data from the 
United Kingdom (UK) demonstrate lower acute cellular rejection episodes in women 
conceiving at > 12 months compared to < 12 months post LT (11% vs 46%, respectively, 
p=0.001),(26) highlighting the importance of stable graft function prior to conception. A 
recent analysis of US Medicare data described elevated rates of graft loss with 
conception up to 24 months after KT.(27) Pre-existing hypertension and severity of graft 
dysfunction prior to conception have been shown to be independently associated with 
graft failure in KT recipients.(28-30) Complicating this relationship between pregnancy 
and rejection is the potential need for increased tacrolimus dosing during pregnancy. 
Tacrolimus is highly protein bound, and concentrated within red blood cells (RBC). 
Increased total body water dilutes RBC counts and albumin, affecting tacrolimus levels. 
While total tacrolimus concentrations decline in pregnancy, it is uncertain whether there 
is disproportionate reduction in bound versus free tacrolimus levels.(31) One study 
reported need for 20-25% increased dose to maintain target levels(32), though over 
aggressive increase in tacrolimus during pregnancy may lead to tacrolimus toxicity.. 
 
Fetal/Infant risks 
Transplant recipients are at increased risk for developing pre-eclampsia. Pre-eclampsia 
is more common in KT than LT recipients, although in both populations the prevalence of 
is ~ 5 times greater than in non-transplant controls.(22-24). Pre-eclampsia in transplant 
recipients may contribute to their increased rate of cesarean deliveries and higher 
prevalence of pre-term births. Aspirin use is often advised during pregnancy to reduce 
their risk of pre-eclampsia.  
 
Immunosuppression and fetal outcomes 
 In 2015 the FDA began replacement of former pregnancy risk letter categories (ie 
A, B, C, D and X) with revised labeling including dosing, potential fetal risks, and registry 
outcome data. In the following section, pregnancy outcomes by IMS will be therefore be 
discussed in broad categories based on available evidence, including: 1.“Generally 
considered safe”-ie calcineurin inhibitors (cyclosporine and tacrolimus), prednisone and 
azathioprine; 2.”Contraindicated during pregnancy” -ie mycophenolate mofetil and 
mycophenolic acid, 3. “Not enough information” -ie sirolimus, everolimus, and 
belatacept.  
  
Calcineurin Inhibitors 
 The calcineurin inhibitors (CNIs) cyclosporine and tacrolimus are the cornerstone 
of modern IMS, and commonly used in pregnancy. Early concerns regarding increased 
risk of birth defects with cyclosporine and tacrolimus have not been demonstrated in 
larger studies, and rates of birth defects in women using CNIs are similar to the general 
population(25, 33). Although a higher incidence of prematurity and low birthweight have 
been reported in offspring of mothers using CNIs, although this finding could relate to 
underlying comorbidities in transplanted mothers, rather than CNI-related side effects.  
 
Mycophenolic Acid Products (MPAs) 
 MPAs including mycophenolate mofetil (MMF) and enteric-coated 
mycophenolate sodium (EC-MPS), carry the greatest known risks to the developing 
fetus. Spontaneous abortions occur in ~ 45% of women using this agent at the time of 
conception, and approximately 22% of children born to mothers using MPAs have 
developmental anomalies (34, 35). Birth defects associated with MPA use include oral-
facial, esophageal, cardiac, and renal abnormalities, as well as microtia, a defect in the 
development of the external ear that is more specific to MPA exposure.(36) For women 
seeking pregnancy, strategies such as temporary replacement of MPA with azathioprine 
along with adding or increasing prednisone should be considered. This strategy is not 
associated with increased risk of acute rejection during pregnancy or postpartum 
period(37). Compared to KT recipients who remain on MPA in early pregnancy, those 
that discontinue MPA preconception have more live births, with an incidence of birth 
defect that is similar to the general population (Table 2).(37) Women of childbearing 
potential should use two forms of highly effective contraception while taking MPA, and 
discontinue this agent at least 6 weeks prior to conceiving. Providers should report 
patients that have conceived while using MPA, or within 6 weeks of stopping this agent, 
to the Mycophenolate Risk Evaluation and Mitigation Strategy (REMS), an FDA 
mandated program that collects pregnancy outcome data and provides patient and 
provider education.(38) 
 
Azathioprine 
 Azathioprine has not been associated with increased risk of fetal anomalies in 
humans.(39, 40)  While preterm delivery and fetal growth restriction have been noted, 
this may be attributable to maternal comorbidities and not necessarily a drug-related 
side effect. Transplant recipients are often switched from MPA products to azathioprine 
in preparation for conception. One study of n=69 recipients (n= 46 KT and no LT 
recipients) switched to MPA at least 6 weeks prior to conception found no increased risk 
of spontaneous abortions or birth defects as compared to those who did not switch MPA 
prior to pregnancy.(41) Azathioprine is therefore considered a safe IMS option in 
pregnancy.   
 
Prednisone  
 Prednisone at maintenance dose is generally considered safe in pregnancy.  A 
meta-analysis of non-transplant women using corticosteroids in the first trimester found 
no higher rate of major anomalies. A prior report of cleft palate in children exposed to in 
utero steroids was not confirmed in follow-up studies.(42, 43)   
 Sirolimus and Everolimus  
 In animal studies, in utero sirolimus exposure results in decreased fetal weights, 
delayed ossification and increased fetal mortality. However, no malformations have been 
noted in human case reports to date.(44) TPR data of n=19 sirolimus exposed women  
identified 2 with birth defects.(25) There have been 2 reported KT recipients and 2 heart 
transplant recipients with everolimus use in the first trimester. Outcomes included 5 live 
births, 1 birth defect, and 1 miscarriage.(25) Given the small number of reports, definitive 
recommendations about the safety of sirolimus and everolimus in pregnancy cannot yet 
be provided. 
 
Belatacept  
 In the TPR there have been 2 reported KT recipients taking belatacept 
throughout 3 pregnancies. The first had two unplanned pregnancies, one 11-week 
miscarriage (concomitant MPA exposure for the first 3 weeks) and one healthy infant. 
The second recipient had a planned pregnancy, switched from MPA to azathioprine ~ 1 
month pre-conception, and delivered a healthy infant. Both recipients had normal graft 
function at last TPR follow-up.(25) There are no additional reports of belatacept use in 
pregnancy, therefore its use cannot be recommended. 
 
Breastfeeding After Transplant:  
Breastfeeding has substantial benefits to mother and child and for the general 
population, the American Academy of Pediatrics (AAP) advises exclusive breast-feeding 
for the first 6 months of life.(45) Within the transplant setting, the number of women that 
choose to breastfeed continues to grow (Figure 2). While IMS during breastfeeding could 
potentially render the mother and infant more susceptible to infections, formal studies of 
these risks have not been conducted.  
 
The AAP previously provided breastfeeding recommendations by drug exposure, but 
now advises patients and practitioners to consult the online LACTMED database.(46) 
LACTMED is maintained by the National Institutes of Health and uses updated registry 
and literature reviews to provide pharmacokinetic information and safety 
recommendations. Corticosteroids have long been considered safe by the AAP with 
ongoing data from LACTMED supporting its use in nursing. In one study, the 
concentration of corticosteroids within the breastmilk of women taking 10-80 mg of 
prednisolone per day was between 5-25% of maternal serum concentrations. 
Azathioprine is also considered safe in breastfeeding, with safety data deriving from both 
the transplant setting and women with inflammatory bowel disease.(46, 47) At doses up 
to 200 mg per day there is low to unmeasurable active metabolites identified in 
breastmilk or infant blood.(48) There have been no reported adverse effects on 
immunity, infection or growth in children followed up to 3.5 years, though longer follow-
up data are lacking.(49)  Cyclosporine and tacrolimus are both measurable in breastmilk, 
although in small quantities that are unlikely to cause harm to nursing infants. In a study 
of six exposed infants, only one had detectable cyclosporine concentrations and had 
normal development up to one year.(50) Estimated infant exposure to weight adjusted 
maternal cyclosporine dose is 0.33%.(51) Similarly estimated infant exposure when 
breastfed by mothers taking tacrolimus is low (0.23%). One study found that infant 
tacrolimus concentrations were lower than maternal concentrations after delivery and 
became undetectable by two weeks postpartum, regardless if they were bottle or 
breastfed.(52) Therefore CNIs are also likely safe for nursing.(46) In contrast, 
breastfeeding while using MPAs, everolimus or sirolimus is not recommended given lack 
of data on drug excretion in breast milk.  
 
Summary: The majority of reproductive aged women will have restoration of fertility 
following kidney and liver transplant, which may occur within weeks to months of their 
surgery. Family planning should be discussed at the first post-operative visit to ensure 
timely initiation of contraception. Counseling must also include a discussion of 
pregnancies desires to ensure that conception is planned at a time that is safest for both 
the mother and baby. Pregnancy in the setting of solid abdominal organ transplant is 
higher risk than in the general population, and includes increased risk of diabetes, 
hypertension, as well as complications such as pre-eclampsia. Nonetheless, most 
transplant recipients will have successful deliveries with healthy offspring. 
Immunosuppressive medications must be tailored for conception plans to ensure use of 
regimens that provide optimal graft outcomes while minimizing infant risk. A growing 
number of transplanted women are enjoying the benefits of breastfeeding, though 
lactation safety based on immunosuppression must be discussed. With these goals in 
mind, transplant providers can help to optimize the health of pregnant mothers, their 
allografts, and their infants. 
  
 Kidney Liver 
Female Recipients 1031 257 
Mean age at 1st transplant  (yrs) 24 ± 6 21 ± 9 
Pregnancies 1867 487 
Mean transplant-conception 
interval (yrs) 
5.3 ± 4 7.6 ± 6.5 
Unplanned  39% 41% 
Estimated conception range July 1967 – June 2016 Nov 1985 – Feb 2016 
During Pregnancy 
Primary Immunosuppressant1 CsA Tac Other CsA Tac Other None 
46% 29% 25% 39% 57% <1% 3% 
MPA exposure  8.2% 5.5% 
Sirolimus exposure 1.3% 1.6% 
Azathioprine exposure 72% 22% 
Hypertension treated  55% 23% 
Diabetes treated 8% 8% 
Preeclampsia 30% 21% 
Rejection2 0.9% 3.4% 
After Pregnancy 
Postpartum rejection2 1.4% 4.2% 
Graft loss within 2 yrs of 
pregnancy outcome 
5.9% (110 losses) 3.5% (17 losses) 
OUTCOMES3 1932 502 
Live births 75% 73% 
  Neonatal deaths 1.5% 1.1% 
Miscarriages 18% 22% 
  MPA exposure4 15.3% 17% 
Stillbirths 2% 1% 
Ectopic pregnancies 1% 1% 
Terminations 4% 4% 
LIVE BIRTHS 1453 364 
Mean gestational age (wks) 35.9 ± 3.4 36.6 ± 3.4 
  Premature (<37 wks) 50% 39% 
  Early Preterm (<34 wks) 20% 16% 
Mean birth weight (g) 2572 ± 764 2740 ± 787 
  Low (<2500 g) 42% 30% 
  Very Low (<1500 g) 10% 8% 
Cesarean section 53% 46% 
Birth Defects 4.4% 4.7% 
Child follow-up (yrs)  14.1 ± 9.6 9.1 ± 7.1 
Recipient follow-up (yrs) 14.8 ± 9.7 10.3 ± 7.4 
Maternal deaths 18.8% 14% 
Mean age of child at maternal 
death (yrs) 
   Number of children 
16.4 ± 8 
 
237 children 
10.4 ± 6.5 
 
43 children 
Adequate graft function at last 
follow-up 
67% 81% 
1 cyclosporine or its modified form (CsA); tacrolimus (Tac); sirolimus, everolimus, mycophenolic acid 
products, or belatacept (other); mycophenolic acid products (MPA); 2 biopsy-proven treated acute 
rejection;  3 includes multiple births; 4 % of miscarriages with reported 1st trimester MPA exposure 
 
(TPR Annual Report 2016) 
  
 
Table 2 Pregnancy outcomes in kidney transplant recipients by pre-pregnancy 
Mycophenylate Product (MPA) cessation in the Transplant Pregnancy Registry 
  
MPA exposure during 
pregnancy 
MPA discontinued pre-
conception 
p 
value 
Recipients/Pregnancies 96/142 188/302   
Unplanned pregnancies 59% 15% <0.001 
Conception Age (yrs) 29.1±4.6 31.9±4.6 <0.001 
Transplant to conception interval 
(yrs) 
3.9±2.8 5.6±3.7 <0.001 
Creatinine before pregnancy 
(mg/dL) 
1.3±0.4 1.1±0.3 <0.001 
Creatinine during 1.4±0.8 1.2±0.6 0.006 
Creatinine postpartum 1.5±0.8 1.2±0.5 <0.001 
Biopsy proven acute rejection 
during 
4.3% 1.3% 0.08 
Biopsy proven acute rejection 
postpartum 
5.1% 1.4% 0.04 
Pregnancy Outcomes       
Live births 48% 78% <0.001 
Miscarriages 48% 20% <0.001 
Stillbirths 1% 1% NS 
Ectopic pregnancies 0 1% NS 
Terminations 3% 0.3% NS 
Live births 69 246   
Mean gestational age (wks) 35.3±3.3 35.7±3.5 NS 
Premature (<37 wks) 55% 48% NS 
Mean birthweight (g) 2406±759 2549±756 0.07 
Low birthweight (<2500 g) 49% 39% NS 
Birth defects (live born) 11.6%* 5.7% NS 
 
      
*Includes 61% MPA-related defects. Percentage does not include MPA-related defects found in 1 
stillbirth and 1 termination. 
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